Search clinical trials for: LDK378(Ceritinib)

Total 494 results

Novartis Pharmaceuticals

Terminated

Ceritinib Rare Indications Study in ALK+ Tumors

Glioblastoma | Anaplastic Large Cell Lymphoma | Inflammatory Myofibroblastic Tumor | Tumors With Aberrations in ALK

France, Czechia, Italy, Spain, Korea, Republic of, Thailand, Israel, Denmark
Novartis Pharmaceuticals

Completed

LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.

Non-Small-Cell Lung Cancer

Japan
Novartis Pharmaceuticals

Available

Managed Access Programs for LDK378, Ceritinib

Non-small Cell Lung Cancer (NSCLC) | Anaplastic Lymphoma Kinase (ALK)- Positive Tumors
Novartis Pharmaceuticals

Completed

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Canada, Taiwan, United States, Italy, Korea, Republic of, Thailand, Belgium, Germany, Austria, Turkey, Greece, United Kingdom, Colombia, India, Malaysia, Brazil, Spain, Poland, Bulgaria, Australia, Czechia, Lebanon, Netherlands, Russian...
Anne Beaven, MD
Novartis

Withdrawn

Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies

Hematologic Malignancies

United States
Yonsei University

Unknown

A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Korea, Republic of
National Health Research Institutes, Taiwan
National Taiwan University Hospital; National Cheng-Kung University Hospital

Terminated

A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma

Cholangiocarcinoma

Taiwan
Novartis Pharmaceuticals

Completed

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

Tumors Characterized by Genetic Abnormalities of ALK

Australia, Belgium, Germany, Netherlands, Spain, Italy, Singapore, Korea, Republic of, United Kingdom, United States, Canada
Novartis Pharmaceuticals

Completed

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib

Non-Small Cell Lung Cancer

Canada, Italy, United Kingdom, Spain, Netherlands, Singapore, Germany, Hong Kong, Japan, France, Korea, Republic of, United States
Novartis Pharmaceuticals

No longer available

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Non-small Cell Lung Cancer (NSCLC)

United States, Argentina, Korea, Republic of, Hong Kong, Thailand, Mexico, Jordan, Colombia, India, Philippines
Novartis Pharmaceuticals

Completed

Effect of Hepatic Impairment on LDK378 Pharmacokinetics

Normal Hepatic Function | Impaired Hepatic Function

United States
Novartis Pharmaceuticals

Completed

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

United Kingdom, Taiwan, Belgium, Spain, Canada, Italy, Singapore, Japan, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Norway, Australia, France, Sweden, United States, New Zealand
Novartis Pharmaceuticals

Completed

Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)

ALK-activated Tumors

France, Spain, Germany, Italy, Korea, Republic of, Canada, Australia, United Kingdom, Netherlands, United States
Novartis Pharmaceuticals

Completed

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Non-Small Cell Lung Cancer

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC

Belgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
Novartis Pharmaceuticals

Terminated

Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)

Tumors With Aberrations in ALK or ROS1

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Preliminary Efficacy for LDK378 in Japanese Patients With Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Tumors Characterized by Genetic Alterations in Anaplastic Lymphoma Kinase (ALK)

Japan
Novartis Pharmaceuticals

Completed

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

Non-small Cell Lung Cancer | Anaplastic Lymphoma Kinase (ALK)

Australia, Spain, Singapore, Italy, United States
Novartis Pharmaceuticals

Completed

A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges (Ascend-7)

ALK-positive Non-small Cell Lung Cancer

United States, France, Italy, United Kingdom, Taiwan, Turkey, Belgium, Germany, Canada, Singapore, Spain, Korea, Republic of, Netherlands, Russian Federation, Brazil, Hong Kong, Australia
Yonsei University

Unknown

An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
Novartis Pharmaceuticals

Completed

A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer

Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma

China
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

Taiwan, Spain, Italy, United States, Korea, Republic of, France
Novartis Pharmaceuticals

Completed

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Non-Small Cell Lung Cancer

Italy, Spain, Taiwan, Germany, Netherlands, Singapore, Austria, Japan, Australia, France, Russian Federation, Sweden, Thailand, Korea, Republic of, Lebanon, Norway, United Kingdom, China, India, Brazil, Turkey, Poland, Denmark, Greece, ... and more
University of California, San Francisco

Terminated

Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma

ALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditions

United States
St. Joseph's Hospital and Medical Center, Phoenix
Novartis; Wayne State University; Translational Genomics Research Institute

Completed

Preoperative Ceritinib (LDK378) in Glioblastoma Multiforme and CNS Metastasis

Glioblastoma | Brain Metastases

United States
Novartis Pharmaceuticals

Recruiting

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

ALK Positive Malignancies

Germany, France, Australia, Belgium, Italy, Korea, Republic of, Poland, China, United States, Taiwan, Brazil, Bulgaria, Hong Kong, Japan, Lebanon, Malaysia, Spain, Russian Federation, Colombia, Singapore, Czechia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK Positive

United States
Criterium, Inc.
University of Colorado, Denver; Novartis

Terminated

Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Cholangiocarcinoma | Esophageal Adenocarcinoma | Colorectal Adenocarcinoma | Hepatocellular Adenocarcinoma

United States
Sun Yat-sen University

Unknown

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. (NEGOTIATE)

Lung Cancer

China
Yael P Mosse
Novartis Pharmaceuticals; Foundation Medicine

Terminated

Next Generation Personalized Neuroblastoma Therapy (NEPENTHE)

Cancer | Neuroblastoma

United States
Pierre Fabre Medicament

Not yet recruiting

Treatment Patterns of Neratinib in HER2+ EBC in China

Breast Cancer

China
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 in Tumors

Breast Neoplasms

United States
Puma Biotechnology, Inc.

Completed

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Tumors

Japan
Puma Biotechnology, Inc.

Completed

Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Healthy Subjects

United States
Pfizer

Recruiting

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. (DELINOR)

Non-Small Cell Lung Cancer

Norway
Puma Biotechnology, Inc.

Completed

Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Healthy Subjects

United States
Puma Biotechnology, Inc.

Completed

Study Evaluating HKI-272 Administered to Healthy Subjects

Healthy

United States
UNC Lineberger Comprehensive Cancer Center

No longer available

Single Subject Neratinib in Bladder Cancer (NRR)

Bladder Cancer

United States
Pierre Fabre Pharma GmbH
iOMEDICO AG; Pierre Fabre Pharma Austria; Pierre Fabre Pharma AG

Active, not recruiting

Real-life Pan-HER-blockade With Neratinib (ELEANOR)

Breast Neoplasm

Austria, Germany, Switzerland
Pfizer

Completed

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

ALK-positive NSCLC

Sweden
Puma Biotechnology, Inc.

Completed

A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

Healthy

United States
Puma Biotechnology, Inc.

Withdrawn

Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Healthy
Convalife (Shanghai) Co., Ltd.

Not yet recruiting

Neratinib Tablets in the Treatment of Advanced NSCLC With Rare EGFR Mutations (CVL009-2001)

NSCLC

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Hutchison Medipharma Limited

Unknown

HMPL-813 in Treating Patients With Glioblastoma

Glioblastoma

China
Sun Yat-sen University
Wu Jieping Medical Foundation

Completed

Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg

Non-small Cell Lung Cancer

China
Shanghai Fosun Pharmaceutical Industrial Development...

Recruiting

A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Advanced Solid Tumor | Advanced Cancer | Lung Cancer, Nonsmall Cell

China
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)

Non-small Cell Lung Cancer
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
Hutchison Medipharma Limited

Completed

A Phase I Study of Epitinib(HMPL-813) in Patients With Advanced Solid Tumors

Solid Tumor

China

Search clinical trials for: LDK378(Ceritinib)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations